A Trial to Evaluate the Efficacy and Safety of Ninerafaxstat in Patients With Symptomatic Non-obstructive Hypertrophic Cardiomyopathy

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(23 sites)

United States

Imbria Investigational Site, La Jolla, California

Imbria Investigational Site, San Francisco, California

Imbria Investigational Site, Washington D.C., District of Columbia

Imbria Investigational Site, Chicago, Illinois

Imbria Investigational Site, Boston, Massachusetts

Imbria Investigational Site, Burlington, Massachusetts

Imbria Investigational Site, St Louis, Missouri

Imbria Investigational Site, Houston, Texas

Imbria Investigational Site, Charlottesville, Virginia

France

Imbria Investigational Site, Montpellier

Imbria Investigational Site, Paris

Imbria Investigational Site, Saint-Herblain

Poland

Imbria Investigational Site, Katowice

Portugal

Imbria Investigational Site, Guimarães

Imbria Investigational Site, Lisbon

Spain

Imbria Investigational Site, Barcelona, Barcelona

Imbria Investigational Site, A Coruña, Galicia

Imbria Investigational Site, Madrid, Madrid

Imbria Investigational Site, Vigo, Pontevedra

Imbria Investigational Site, Seville, Sevilla

United Kingdom

Imbria Investigational Site, London, England

Imbria Investigational Site, Glasgow, Scotland